IL22 and head and neck squamous cell carcinoma: Mei et al. selected MUC1 as the target of CAR-T cells and engineered a fourth generation of CAR-T cells secreting IL-22 for the treatment of MUC1-positive HNSCC tumors in a xenograft mice model.